| Literature DB >> 28451380 |
Yan Press1,2,3, Boris Punchik1,2,3, Ella Kagan2,3, Alex Barzak2, Tamar Freud1.
Abstract
BACKGROUND: The overall implementation rate for outpatient comprehensive geriatric assessment (OCGAU) recommendations ranges from 48.6 to 71%. The purpose of the study was to identify factors that reduce the implementation rate of geriatric recommendations.Entities:
Keywords: Adherence; Assessment; Outpatient
Mesh:
Year: 2017 PMID: 28451380 PMCID: PMC5404663 DOI: 10.1186/s13584-017-0134-7
Source DB: PubMed Journal: Isr J Health Policy Res ISSN: 2045-4015
Ten more frequent recommendation to add/increase dose of drug or stope/decrease dose of drug, and rates of implementations
| Type of recommendations | N recommendations | N of implemented recommendations | Implementation rate |
|---|---|---|---|
|
| |||
| Calcium and vitamin D supplementation | 174 | 100 | 57.5 |
| Antidepressants | 169 | 97 | 57.4 |
| Cholinesterase inhibitors/ Memantine | 72 | 54 | 75.0 |
| Non-opioid analgetics | 56 | 30 | 53.6 |
| Antiresorptive drugs | 33 | 17 | 51.5 |
| ACE- inhibitors | 23 | 10 | 43.5 |
| Statins | 22 | 12 | 54.5 |
| Beta- blockers | 18 | 6 | 33.3 |
| Neuroleptics | 15 | 9 | 60.0 |
| Diuretics | 14 | 2 | 14.3 |
|
| |||
| Benzodiazepines/ Z-drugs | 91 | 39 | 42.9 |
| Multivitamins | 58 | 25 | 43.1 |
| Diuretics | 53 | 30 | 56.6 |
| Calcium channel blockers | 44 | 15 | 34.1 |
| Statins | 33 | 19 | 57.6 |
| Sulfonylurea | 27 | 12 | 44.4 |
| Anticholinergic agents | 26 | 12 | 46.2 |
| Nitrates | 23 | 8 | 34.8 |
| ACE-inhibitors | 23 | 10 | 43.5 |
| Propoxyphene | 23 | 18 | 78.3 |
Socio-demographic and health-related characteristics of patients in the entire study group and in the sub-groups categorized by recommendation implementation
| Q1- Implementation 0–24% ( | Q2- Implementation 25–49% ( | Q3- Implementation 50-50–74% ( | Q4- Implementation 75–100% ( |
|
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % |
| % | ||||
| Gender | Male | 39 | 31.5 | 37 | 35.9 | 54 | 37.8 | 38 | 32.2 | 0.67 | 0.98 |
| Female | 85 | 68.5 | 66 | 64.1 | 89 | 62.2 | 80 | 67.8 | |||
| 124 | 103 | 143 | 118 | ||||||||
| Age (years) | Mean ± SD | 83.7 ± 6.5 | 83.8 ± 6.0 | 83.6 ± 5.5 | 83.5 ± 5.9 | 0.972 | 0.775 | ||||
| Range | 67–100 | 70–103 | 69–97 | 67–96 | |||||||
| 124 | 103 | 143 | 118 | ||||||||
| Family Status | Married | 47 | 42.7 | 44 | 49.4 | 55 | 48.2 | 47 | 51.6 | 0.62 | 0.263 |
| Other | 63 | 57.3 | 45 | 50.6 | 59 | 51.8 | 44 | 48.4 | |||
| 110 | (mis = 14) | 89 | (mis = 14) | 114 | (mis = 29) | 91 | (mis = 27) | ||||
| Education (years) | Mean ± SD | 8.8 ± 5.2 | 9.8 ± 4.7 | 9.5 ± 5.2 | 9.3 ± 4.9 | 0.489 | 0.477 | ||||
| Range | 0–20 | 0–20 | 0–20 | 0–20 | |||||||
| 114 | (mis = 10) | 93 | (mis = 10) | 131 | (mis = 12) | 96 | (mis = 22) | ||||
| Barthel Index | Mean ± SD | 82.8 ± 16.2 | 84.1 ± 16.9 | 84.7 ± 15.8 | 87.0 ± 15.3 | 0.149 | 0.027 | ||||
| Range | 35–100 | 25–100 | 30–100 | 35–100 | |||||||
| 115 | (mis = 9) | 96 | (mis = 7) | 132 | (mis = 11) | 115 | (mis = 3) | ||||
| OARS- IADLa
| Mean ± SD | 7.2 ± 3.5 | 7.4 ± 3.7 | 7.4 ± 3.2 | 8.2 ± 3.7 | 0.126 | 0.03 | ||||
| Range | 0–14 | 0–14 | 0–14 | 14-ינו | |||||||
| 116 | (mis = 8) | 96 | (mis = 7) | 135 | (mis = 8) | 115 | (mis = 3) | ||||
| MMSEb (0–30) | Mean ± SD | 21.33 ± 5.88 | 22.42 ± 5.76 | 21.58 ± 5.41 | 23.02 ± 4.71 | 0.106 | 0.052 | ||||
| Range | 6–30 | 2–30 | 6–30 | 8–30 | |||||||
| 109 | (mis = 15) | 96 | (mis = 7) | 137 | (mis = 6) | 113 | (mis = 5) | ||||
| CDTc (0–10) | Mean ± SD | 6.4 ± 3.2 | 6.6 ± 2.9 | 6.2 ± 2.9 | 6.7 ± 2.9 | 0.56 | 0.51 | ||||
| Range | 0–10 | 0–10 | 0–10 | 0–10 | |||||||
| 111 | (mis = 13) | 98 | (mis = 5) | 137 | (mis = 6) | 115 | (mis = 3) | ||||
| High DSd | Yes | 81 | 83.5 | 68 | 85.0 | 96 | 79.3 | 76 | 79.2 | 0.65 | 0.55 |
| No | 16 | 16.5 | 12 | 15.0 | 25 | 20.7 | 20 | 20.8 | |||
| 97 | (mis = 27) | 80 | (mis = 23) | 121 | (mis = 22) | 96 | (mis = 22) | ||||
| CCITSe | Mean ± SD | 2.5 ± 1.9 | 2.4 ± 2.0 | 2.2 ± 1.7 | 1.8 ± 1.7 | 0.029 | 0.0044 | ||||
| Range | 0–8 | 0–11 | 0–8 | 0–8 | |||||||
| 105 | (mis = 19) | 96 | (mis = 7) | 117 | (mis = 26) | 92 | (mis = 26) | ||||
| Number of medications per month | Mean ± SD | 7.87 ± 4.43 | 8.35 ± 4.28 | 8.13 ± 4.32 | 8.19 ± 4.41 | 0.768 | 0.434 | ||||
| Range | 1.0–23.7 | 1.0–23.7 | 1.3–26.0 | 0.7–29.7 | |||||||
| 115 | (mis = 9) | 94 | (mis = 9) | 132 | (mis = 11) | 105 | (mis = 13) | ||||
P* among all Q groups, P** between Q1/Q4
aOARS-IADL- the Older Americans Resources and Service Instrumental Activity of Daily Living; bMMSE- Mini-mental State Examination; cCDT-Clock drawing test; dHigh DS- High depression score: a composite score comprised of patients with a GDS-15 score ≥ 5, or a PHQ-9 score ≥10; eCCITS- the Charlson Comorbidity Index- Total Score
Distribution of types of recommendation, by implementation group
| Q1- Implementation 0–24% ( | Q2- Implementation 25–49% ( | Q3- Implementation 50–74% ( | Q4- Implementation 75–100% ( | All ( |
|
| |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean ± SD | Range |
| Mean ± SD | Range |
| Mean ± SD | Range |
| Mean ± SD | Range |
| Mean ± SD | Range |
| |||
| Add/increase dose of drug | 2.0 ± 1.0 | 1–5 | 97 | 1.9 ± 1.0 | 1–5 | 87 | 2.1 ± 1.2 | 1–5 | 111 | 1.9 ± 1.1 | 1–5 | 94 | 2.0 ± 1.1 | 1–5 | 389 | 0.65 | 0.44 |
| Stop/decrease dose of drug | 2.3 ± 1.5 | 1–7 | 74 | 2.1 ± 1.3 | 1–7 | 58 | 2.3 ± 1.5 | 1–7 | 90 | 2.0 ± 1.4 | 1–6 | 68 | 2.2 ± 1.5 | 1–7 | 290 | 0.86 | 0.98 |
| All pharmacologic recommendations | 3.3 ± 1.8 | 1–9 | 110 | 2.9 ± 1.75 | 1–9 | 96 | 3.2 ± 2.1 | 1–10 | 137 | 3.2 ± 1.9 | 1–9 | 103 | 3.2 ± 1.9 | 1–10 | 446 | 0.63 | 0.76 |
| Laboratory tests | 2.1 ± 1.2 | 1–6 | 52 | 1.7 ± 1.1 | 1–7 | 53 | 2.3 ± 1.3 | 1–5 | 62 | 2.0 ± 1.2 | 1–7 | 63 | 2.0 ± 1.2 | 1–7 | 230 | 0.08 | 0.78 |
| Imaging and other diagnostic tests | 1.4 ± 0.6 | 1–4 | 73 | 1.4 ± 0.7 | 1–4 | 61 | 1.5 ± 0.8 | 1–5 | 71 | 1.6 ± 0.7 | 1–3 | 50 | 1.5 ± 0.7 | 1–5 | 255 | 0.61 | 0.15 |
| “MD” referral | 1.5 ± 0.7 | 1–1 | 56 | 1.5 ± 0.6 | 1–3 | 63 | 1.6 ± 0.9 | 1–4 | 63 | 1.4 ± 0.7 | 1–3 | 45 | 1.5 ± 0.7 | 1–4 | 207 | 0.44 | 0.52 |
| “Non-MD” referral | 1.4 ± 0.6 | 1–1 | 90 | 1.4 ± 0.5 | 1–2 | 64 | 1.3 ± 0.5 | 1–3 | 90 | 1.3 ± 0.5 | 1–3 | 71 | 1.4 ± 0.5 | 1–4 | 315 | 0.53 | 0.42 |
| Immunization | 1.9 ± 0.8 | 1–3 | 62 | 1.9 ± 0.8 | 1–3 | 60 | 1.8 ± 0.8 | 1–3 | 77 | 1.4 ± 0.5 | 1–3 | 53 | 1.8 ± 0.8 | 1–3 | 252 | 0.019 | 0.002 |
| Total | 7.2 ± 3.5 | 1–17 | 124 | 7.1 ± 3.3 | 3–18 | 103 | 7.3 ± 3.7 | 2–18 | 143 | 6.5 ± 3.6 | 1–15 | 118 | 7.0 ± 3.6 | 1–18 | 488 | 0.27 | 0.11 |
P* among all Q groups, P** between Q1/Q4
Comparison of primary physicians by implementation group
| Physician characteristics | Q1- Implementation 0–24% ( | Q2- Implementation 25–49% ( | Q3- Implementation 50–74% ( | Q4- Implementation 75–100% ( | All ( |
|
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % |
| % |
| % | ||||
| Gender | Male | 35 | 28.2 | 20 | 19.4 | 30 | 21.0 | 29 | 24.6 | 114 | 23.4 | 0.38 | 0.56 |
| Female | 89 | 71.8 | 83 | 80.6 | 113 | 79.0 | 89 | 75.4 | 374 | 76.6 | |||
| 124 | 103 | 143 | 118 | 488 | |||||||||
| Experience (years) | Mean ± SD | 14.2 ± 7.0 | 14.1 ± 6.1 | 14.3 ± 6.6 | 14.5 ± 6.6 | 14.3 ± 6.6 | 0.81 | 0.69 | |||||
| Range | 2–39 | 2–35 | 2–36 | 3–37 | 2–39 | ||||||||
| 123 | (mis = 1) | 100 | (mis = 3) | 138 | (mis = 5) | 111 | (mis = 7) | 472 | (mis = 16) | ||||
| Specialty | Family Medicine | 91 | 73.4 | 72 | 69.9 | 101 | 70.6 | 79 | 66.9 | 343 | 70.3 | 0.52 | 0.3 |
| General Medicine | 11 | 8.9 | 18 | 17.5 | 21 | 14.7 | 18 | 15.3 | 68 | 13.9 | |||
| No specialization | 22 | 17.7 | 13 | 12.6 | 21 | 14.7 | 21 | 17.8 | 77 | 15.8 | |||
| 124 | 103 | 143 | 118 | 488 | |||||||||
P* among all Q groups, P**between Q1/Q4